NICE Archives - Page 44 of 46 -

Market access webinar Widescreen size NEW v6

Audio/ Cancer/ Debates/ Debates/ Debates & Insight/ Debates & Insight/ Market Access/ Oncology/ Webinars/ Webinars On demand

Available on demand: Cancer Treatment Access: Strategy, Approach, Outcomes

Louise Bellamy cancer, commercial, HEOR, IMS Health, market access, marketing, NHS, NICE, Oncology, pharma 0 Comment

Available on demand: A one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.

Available on demand: Cancer Treatment Access: Strategy, Approach, Outcomes

https://pharmaphorum.com/debates-insight-oncology/cancer-treatment-access-strategy-approach-outcomes/

News/ Pharma Market Access

NICE recommends BMS melanoma combination

Richard Staines Bristol-Myers Squibb, cancer, immunotherapy, melanoma, NICE, Oncology 0 Comment

NICE makes swift decision on skin cancer treatment.

NICE recommends BMS melanoma combination

https://pharmaphorum.com/news/nice-recommends-bms-melanoma-combination/

News/ Pharma Market Access

Father petitions NHS to fund kidney drug for son

Richard Staines Digital / Social media, market access, nephrology, NICE, pricing, Rare diseases, reimbursement 0 Comment

But NHS refuses £340,000 a year treatment.

Father petitions NHS to fund kidney drug for son

https://pharmaphorum.com/news/father-petitions-nhs-fund-kidney-drug-son/

News/ Pharma Market Access

NICE rejects Janssen’s CLL drug

Richard Staines cancer, Cancer Drugs Fund, chronic lymphocytic leukaemia, Haematology, market access, NICE 0 Comment

Drug may be paid for by Cancer Drugs Fund

NICE rejects Janssen’s CLL drug

https://pharmaphorum.com/news/nice-rejects-janssens-cll-drug/

Articles/ Views and analysis

NICE and Highly Specialised Technologies: three years on

Leela Barham Financial, Highly Specialised Technology, HST, Leela Barham, market access, NICE, Rare diseases, UK 0 Comment

Leela Barham examines the process for the appraisal of Highly Specialised Technologies.

NICE and Highly Specialised Technologies: three years on

https://pharmaphorum.com/views-and-analysis/nice-and-highly-specialised-technologies-three-years-on/

News/ Rare diseases

NHS under fire for delaying access to rare disease cholesterol drug

Richard Staines NHS England, NICE, Rare diseases 0 Comment

Pharma concerned by fairness and transparency of NHS England’s Prioritisation Framework

NHS under fire for delaying access to rare disease cholesterol drug

https://pharmaphorum.com/news/nhs-under-fire-for-delaying-access-to-rare-disease-cholesterol-drug/

Articles/ Pharma Market Access/ UK & Europe/ Views and analysis

Should industry pay for NICE Technology Appraisals?

Leela Barham Leela Barham, NHS, NICE, Technology Appraisal 0 Comment

NICE needs to plug a gap in its funding

Should industry pay for NICE Technology Appraisals?

https://pharmaphorum.com/articles/should-industry-pay-for-nice-technology-appraisals/

Articles/ Pharma Market Access/ Views and analysis

Accelerating health technologies with NICE Office for Market Access

Linda Banks Accelerated Access Review, market access, NICE 0 Comment

England’s health watchdog launched its service to speed the delivery of new technologies in October 2015. Policy coordinator

Accelerating health technologies with NICE Office for Market Access

https://pharmaphorum.com/articles/accelerating-health-technologies-with-nice-office-for-market-access/

Articles/ Cancer/ Healthcare/ UK & Europe/ Views and analysis

The new Cancer Drugs Fund: sticking plaster 2.0 or a model for the future?

Linda Banks Cancer Drugs Fund, NHS, NICE 0 Comment

A new, value-based Cancer Drugs Fund is set to be launched in England soon, but pharma companies fear

The new Cancer Drugs Fund: sticking plaster 2.0 or a model for the future?

https://pharmaphorum.com/articles/the-new-cancer-drugs-fund-sticking-plaster-2-0-or-a-model-for-the-future/

Trending

NICE

Login